Register today for this 90-minute webinar and learn what’s new in licensing deals and the implications for dealmaking as we wrap up 2012 and enter the New Year.
The stage appears more competitive with upfronts the same or higher, but milestones and overall deal values are down. Option-to-license deals are still going strong but have leveled off, and universities are playing a more collaborative role in research. When you attend this webinar you will hear more details on these developments, plus receive important information on the America Invents Act (AIA) and how it will affect licenses.
Key Learning Points
- Review of market trends including recent 2012 data.
- Innovative deal trends, including an expansion of alliances between universities and pharmaceutical companies.
- Implications of the AIA on licensing.
Register now to equip yourself with the information you need on licensing deal developments and the impact of the America Invents Act.
Your Expert
Hemmie Chang is a partner at Foley Hoag LLP and chairs the firm’s Licensing & Strategic Alliances Group. She has over two decades of experience advising both pharmaceutical and emerging biotech companies on complex collaboration and licensing transactions. Hemmie is currently advising clients on potential collaborations with Boston Scientific, Lilly and Pfizer.
